Some compounds, such as ruboxistaurin and delcasertib (Figure 3), targeting different PKC isoforms, have indeed entered clinical trials for diverse pathologies (namely, diabetes and related complications, heart diseases and cancer) [41,42,43]; although promising, most of these molecules failed to complete the clinical development process due to both unfavorable clinical outcomes and unexpected side effects [28]. Here, PRRT2 is linked to cancer.